Title: [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20100301
Title: Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100215
Title: Efficacy of selected natural products as therapeutic agents against cancer.
Journal: Journal of natural products 20080301
Title: Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents.
Journal: Anti-cancer drugs 20070901
Title: Glaziovianin A, a new isoflavone, from the leaves of Ateleia glazioviana and its cytotoxic activity against human cancer cells.
Journal: Bioorganic & medicinal chemistry letters 20070601
Title: The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.
Journal: British journal of cancer 20070521
Title: Vascular disrupting agents in clinical development.
Journal: British journal of cancer 20070423
Title: Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy.
Journal: Cancer science 20070401
Title: The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity.
Journal: Anticancer research 20070101
Title: Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
Journal: The Journal of biological chemistry 20060414
Title: Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Journal: Cancer research 20060215
Title: Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro.
Journal: The pharmacogenomics journal 20060101
Title: Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs.
Journal: Anticancer research 20060101
Title: Antitumor activity of TZT-1027 (Soblidotin).
Journal: Anticancer research 20060101
Title: Total assignment of the (1)H- and (13)C-NMR spectra for TZT-1027 and related compounds.
Journal: Chemical & pharmaceutical bulletin 20050901
Title: [Structure-activity relationship analysis].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20040401
Title: TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply.
Journal: Anticancer research 20040101
Title: Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.
Journal: Cancer science 20030901
Title: Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo.
Journal: Cancer chemotherapy and pharmacology 20020101
Title: Validation of an analytical method for a potent antitumor agent, TZT-1027, in plasma using liquid chromatography-mass spectrometry.
Journal: Journal of chromatography. B, Biomedical sciences and applications 20011025
Title: Yamamoto N, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci. 2009 Feb;100(2):316-21.
Title: Fanale D, et al. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015;2015:690916.
Title: Watanabe K, et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Clin Cancer Res. 2010 Feb 15;16(4):1170-8.
